Form 144 is a notice of proposed sale under Rule 144 for affiliates like directors selling restricted securities. Here, Rocket Lab director Merline A. Saintil plans to sell 5,000 common shares via Morgan Stanley on or about 12/19/2025 at an aggregate market value of $299,600 (implying ~$59.92/share). Shares were acquired via restricted stock units from the issuer on 08/22/2023. Saintil reports prior sales within the past 3 months: 10,000 shares on 12/04/2025 ($480,000), 15,000 on 12/12/2025 ($975,000), and 5,000 on 12/17/2025 ($272,321), totaling 30,000 shares for ~$1.73M. Sales rely on a Rule 10b5-1 trading plan adopted 09/17/2025, with certification of no undisclosed material adverse information. Against 534,156,333 shares outstanding, this represents <0.01% dilution, tied to routine RSU vesting in Rocket Lab's launch services business.

Routine pre-planned insider sale under 10b5-1 signals no opportunistic timing or concerns, as Saintil affirms no undisclosed adverse info. Minimal dilution (<0.007%) unlikely to affect stock price or strategy in Rocket Lab's satellite/launch operations. Investors should monitor aggregate insider activity and Q4 2025 results for liquidity or compensation trends.